Clinical Innovation

We translate Preclinical and Epidemiological data into clinical benefits to provide effective therapies and support for patients living with hepatitis C. Clinical studies are conducted to determine whether a new treatment is safe. Such studies are based on healthy volunteers and patients who agree to participate and try new medicines. They are fundamental to the development of innovative medicines that treat Hep C. Those clinical studies are designed and conducted in accordance with the ethical principles of the Declaration of Helsinki Good Clinical Practice guidelines as well as national and international regulatory requirements.

Our clinical innovation is enhanced through our participation in key industry collaborations, dedicated to quickly bring innovative new medicines to the public.